GSK GlaxoSmithKline PLC
P/E
15.62
Forward P/E
9.77
Price/Sales
2.987
Beta
0.28
Div Yield
0.0367%
Market Cap
--
Company Analysis
Latest News
GSK Wins FDA Approval for Utebzi, First Oral Alternative to IV Antibiotics
GSK and Spero Therapeutics received FDA approval for Utebzi (tebipenem pivoxil) to treat complicated urinary tract infections (cUTIs) and pyelonephritis. This...
GSK Buys Nuvalent for $10.6 Billion, Its Largest Deal of 2026
GSK agreed to acquire Nuvalent for approximately $10.6 billion. The purchase price is $124 per share. This represents a 40% premium to the last closing price....
GlaxoSmithKline PLC Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
Consensus revenue for Q1 2026 is projected at $10.19 billion alongside an EPS of $1.19, with the current stock price of $54.60 trading near the average analyst...